Read by QxMD icon Read

Future Oncology

Thomas Powles
Thomas Powles speaks to Sebastian Dennis-Beron, Commissioning Editor: Dr. Thomas Powles is a clinical professor of genitourinary oncology and the lead for solid tumor research at Barts Cancer Institute in London. His main research interests are in genital and urinary cancers, in which he leads a spectrum of clinical studies from Phase I to randomized Phase III investigating novel targeted and immune therapies. His research also focuses on correlation of novel biomarkers and aims to define markers with prognostic value that may predict response or resistance to therapy...
July 20, 2017: Future Oncology
Yoshiko Umeyama, Yoshiyuki Shibasaki, Hideyuki Akaza
Treatment options for advanced and metastatic renal cell carcinoma have advanced considerably in the past decade with the approval of several targeted agents, including axitinib. Axitinib is a potent and selective inhibitor of VEGFRs 1-3, and is well established as second-line treatment. This article summarizes factors to be considered when administering axitinib, such as individualized dose titration and axitinib-associated adverse events, in order to retain patients longer on treatment, which would likely lead to improved efficacy outcomes...
July 14, 2017: Future Oncology
Francesco Tovoli, Stefania De Lorenzo, Maria Aurelia Barbera, Ingrid Garajova, Giorgio Frega, Andrea Palloni, Maria Abbondanza Pantaleo, Guido Biasco, Giovanni Brandi
The search for systemic therapies for hepatocellular carcinoma has been characterized by difficulties and failures. Despite recent progresses, many issues are still to be settled. In particular, the development of drugs inhibiting different neoplastic pathways remains a priority for patients intolerant or resistant to antiangiogenic drugs. This task may be daunting, as previous failures extensively demonstrated. We aimed to identify the future perspective of postsorafenib trials analyzing the strengths and the critical points of past and currently undergoing studies, in the light of the most recent evidences in the field...
July 11, 2017: Future Oncology
John R Benson, Ismail Jatoi
The 39th annual San Antonio Breast Cancer Symposium (SABCS) was convened in San Antonio, Texas, on 9-13 December 2016. More than 7000 clinicians and scientists from around the world participated in the symposium which featured a range of presentations and keynote talks pertaining to breast cancer screening, prevention, locoregional and systemic therapies. This two-part report highlights a selection of important studies presented at this premier breast cancer event with Part 1 focusing onmetastatic breast cancer, extended endocrine therapy and the prognostic significance of BRCA1/2 gene mutations...
July 7, 2017: Future Oncology
Xiaoqin Ji, Xixu Zhu, Xueguan Lu
Solid tumors are composed of tumor epithelial cells and the stroma, which are seemingly separate but actually related through cell-cell and cell-matrix interactions. These interactions can promote tumor evolution. Cancer-associated fibroblasts (CAFs) are the most abundant non-neoplastic cells in the stroma and also among the most important cell types interacting with cancer cells. Particularly, cancer cells promote the formation and maintenance of CAFs by secreting various cytokines. The activated CAFs then synthesize a series of growth factors to promote tumor cell growth, invasion and metastasis...
July 7, 2017: Future Oncology
Elie El Rassy, Pamela Abdayem, Joseph Kattan
No abstract text is available yet for this article.
July 7, 2017: Future Oncology
Wei-Lun Chang, Meng-Ying Lin, Hsin-Yu Kuo, Hsiao-Bai Yang, Hsiu-Chi Cheng, Cheng-Chan Lu, Bor-Shyang Sheu
AIM: Whether genetic polymorphisms of osteopontin (OPN) coding gene, SPP1, determine the risk of gastric precancerous intestinal metaplasia (IM) in Helicobacter pylori infected patients. PATIENTS & METHODS: Helicobacter pylori infected patients (100 with and 210 without IM) were recruited to evaluate the associations of SPP1 promoter polymorphisms with gastric IM and adjusted for age, sex and smoking. Gastric OPN expression and inflammation were evaluated by immunohistochemistry, and haemotoxylin and eosin stain...
July 7, 2017: Future Oncology
Andreas Seeber, Christoph Leitner, Kathrin Philipp-Abbrederis, Gilbert Spizzo, Florian Kocher
Systemic therapy options for small cell lung cancer patients with extensive disease remain poor. After an initial response on first-line therapy, virtually all patients develop disease progression. For those who showed an initial response only few therapy options with low response rates are currently available. Until now, many experimental and targeted agents have failed to yield convincing clinical benefits, and new therapy options are clearly warranted for these patients. In this year's oncological congresses, several new therapy strategies, including checkpoint inhibition, showed promising results in ongoing trials...
July 7, 2017: Future Oncology
Umer Salati, Aisling Barry, Frank Y Chou, Roy Ma, David M Liu
Primary liver cancer, mainly hepatocellular carcinoma, is one of the most common malignancies worldwide. Surgical management, either resection or transplantation, is considered definitive treatment, however, less than 20% of patients are ultimately candidates. Thermal ablation modalities such as radiofrequency ablation and microwave ablation have evolved such that these modalities have been applied with curative intent. Moreover, thermal ablation has demonstrated efficacy in treating early-stage tumors and can be offered as first-line treatment in patients with uncomplicated disease...
July 7, 2017: Future Oncology
Smith Giri, Ranjan Pathak, Madan Raj Aryal, Paras Karmacharya, Vijaya Raj Bhatt
No abstract text is available yet for this article.
July 7, 2017: Future Oncology
Kylie H Kang, Jimmy T Efird, Neelesh Sharma, Michael Yang, Afshin Dowlati, Philip Linden, Mitchell Machtay, Tithi Biswas
AIM: Studies have shown increased pretreatment neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios to be predictive of survival in various cancers. Our aim was to evaluate the prognostic role of such inflammatory markers in non-small-cell lung cancer (NSCLC). METHODS: One hundred and sixty-three patients with stage III NSCLC who received definitive treatment were included. Survival analysis was performed using Kaplan-Meier method. Hazard ratios for overall and recurrence-free survival were estimated using Cox proportional hazards model...
July 7, 2017: Future Oncology
Zhi Dong, Jing Gao, Jifang Gong, Jie Li, Yanyan Li, Lin Shen, Jian Li
AIM: To assess the efficacy of second-line sunitinib therapy in gastrointestinal stromal tumor patients with different exon 11 mutation genotypes. PATIENTS & METHODS: Thirty eight of the 75 patients received imatinib (IM) dose escalation followed by sunitinib (IM escalation group), while 37 were switched to sunitinib directly after the failure of first-line IM treatment (sunitinib group). Progression-free survival and overall survival were compared. RESULTS: The median progression-free survival in the sunitinib group was significantly longer than in the IM escalation group (14 vs 9 months; p = 0...
July 7, 2017: Future Oncology
Li Li, Bei-Bei Ni, Qing-Hua Zhong, Yan-Hui Liu, Ming-Hui Zhang, Ke-Ping Zhang, Dai-Ci Chen, Lei Wang
AIM: To investigate the relationship between mutations of key genes in the EGFR signaling pathway and the prognosis of stage II colorectal cancer patients without chemotherapy. MATERIALS & METHODS: The incidence of KRAS, NRAS, BRAF, PIK3CA mutations and deficient DNA mismatch repair were assessed in 160 stage II colorectal cancer patients who had been treated by radical operation without adjuvant chemotherapy. RESULTS: Mutations in KRAS, BRAF or PIK3CA were associated with poor prognosis, while the deficient DNA mismatch repair status was not associated with the prognosis...
July 7, 2017: Future Oncology
Laura Orlando, Saverio Cinieri
No abstract text is available yet for this article.
July 7, 2017: Future Oncology
Mathew A Cherian, Cynthia X Ma
Up to 25% of patients with early-stage HER2+ breast cancer relapse despite adjuvant trastuzumab-based regimens and virtually all patients with metastatic disease eventually die from resistance to existing treatment options. In addition, recent studies indicate that activating HER2 mutations without gene amplification could drive tumor growth in a subset of HER2-ve breast cancer that is not currently eligible for HER2-targeted agents. Neratinib is an irreversible HER kinase inhibitor with activity as extended adjuvant therapy following standard trastuzumab-based adjuvant treatment in a Phase III trial...
June 30, 2017: Future Oncology
Jaafar Bennouna
No abstract text is available yet for this article.
June 28, 2017: Future Oncology
Adalgiza Reyes, Josep Marti, Santiago Marfa, Wladimiro Jimenez, Vedrana Reichenbach, Amalia Pelegrina, Constantino Fondevila, Juan Cg Valdecasas, Josep Fuster
In response to: S Sabour. Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases; rule of thumb.
June 26, 2017: Future Oncology
Siamak Sabour
Response to: Reyes A, Marti J, MarfĂ  S et al. Prognostic prediction by liver tissue proteomic profiling in patients with colorectal liver metastases. Future Oncol. 13(10), 875-882 (2017).
June 26, 2017: Future Oncology
David C Currow, Richard Je Skipworth
Cancer cachexia affects many patients with advanced cancer. This multifactorial syndrome, which involves loss of muscle mass and body weight, profoundly affects patients' physical functioning and quality of life. Pharmacologic interventions that target weight loss and also improve patient-reported measures are required. Anamorelin hydrochloride is an oral ghrelin receptor agonist for the treatment of cancer anorexia-cachexia that stimulates release of growth hormone and insulin-like growth factor 1, and improves food intake and body weight...
June 16, 2017: Future Oncology
Daniela Victoria Pirela Araque, Archie Bleyer, Juan P Brito
Despite the increase in thyroid cancer incidence among adolescents and young adults (AYAs), this group has received limited attention. We reviewed the epidemiology and challenges of thyroid cancer care among AYAs, and proposed a research agenda to improve their care. Thyroid cancer is the most common cancer in American adults 16-33 years of age. AYAs with thyroid cancer face challenges including overdiagnosis reduced healthcare access and inconsistent care. Successful treatment of these patients results in additional challenges due to ongoing side effects of treatment as well as lasting impacts on their quality of life...
June 15, 2017: Future Oncology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"